Влияние комбинированного применения аторвастатина и курцетина на биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («долгий COVID»)

Влияние комбинированного применения аторвастатина и курцетина на биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («долгий COVID»)

Автор: Алиева Р. Б., Фозилов Х. Г., Шек А. Б., Хошимов Ш. У., Мусабаев М. М., Кан Л. Э., Ким А. Р., Ходиметова Ш. А.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Оригинальные статьи

Статья в выпуске: 1, 2023 года.

Бесплатный доступ

Цель: Сравнить влияние монотерапии аторвастатином и комбинированного применения аторвастатина с курцетином (смесь биофлавоноидов куркумина и кверцетина) на липидный спектр и биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («Долгий COVID»).Материал и методы. Проведено открытое простое сравнительное рандомизированное исследование 186 больных с диагнозом: ИБС. Прогрессирующая стенокардия напряжения, в том числе 77 (I группа) пациентов, у которых дестабилизация стенокардии возникла вследствие перенесенного COVID-19 в течение 4-8 недель до включения в исследование, и 109 пациентов (II группа), у которых дестабилизация не имела связи с перенесенной инфекцией.Результаты: В I группе уровень вчС-реактивного белка [5,4 (2,06-7,4) г/л и IL-6 8,6 (5,4-10,3) пг/мл] был выше (Р

Еще

Долгий covid, нестабильная стенокардия, куркумин, кверцетин

Короткий адрес: https://sciup.org/143179919

IDR: 143179919   |   DOI: 10.38109/2225-1685-2023-1-86-92

Список литературы Влияние комбинированного применения аторвастатина и курцетина на биомаркеры воспаления у больных нестабильной стенокардией, после COVID-19 («долгий COVID»)

  • Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265–1273.
  • Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponinpositive COVID-19 patients assessed by cardiovascular magnetic resonance. European Heart Journal. (2021) 1866–1878. doi: 10.3410/f.739571449.793583038
  • Thornton GD, Shetye A, Knight DS, Knott K., et al. Myocardial Perfusion Imaging After Severe COVID-19 Infection Demonstrates Regional Ischemia Rather Than Global Blood Flow Reduction. Front Cardiovasc Med 2021 Dec 7;8:764599. doi: 10.3389/fcvm.2021.764599.eCollection 2021.
  • Venkatesan, P. NICE guideline on long COVID – The Lancet Respiratory Medicine. Lancet Respir. Med. 2021;9(2):129. doi: 10.1016/s2213-2600(21)00031-x
  • Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z
  • Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA 2020 Dec 8;324(22):2251-2252. doi: 10.1001/jama.2020.22717
  • Greenhalgh, T., Knight, M., Buxton, M. & Husain, L. Management of post-acute Covid-19 in primary care. BMJ 2020 Aug 11;370:m3026. doi: 10.1136/bmj.m3026
  • An Y-W, Song S, Li W-X, Chen Y-X et al. Liver function recovery of COVID-19 patients after discharge, a follow-up study. Int J Med Sci 18: 176–186, 2021. doi:10.7150/ijms.50691
  • Wang Y, Liu S, Liu H, Li W et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 73: 807-816, 2020. doi:10.1016/j.jhep.2020.05.002
  • Spearman CW, Aghemo A, Valenti L, Sonderup MW. COVID-19 and the liver: a 2021 update. Liver Int 41: 1988–1998, 2021. doi:10.1111/liv.14984
  • Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot, and Elaine Y. Wan. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022 Jan 1;322(1):C1-C11. doi: 10.1152/ajpcell.00375.2021
  • Raman B, Bluemke DA, Lüscher TF, and Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus European Heart Journal. 2022 Mar 14;43(11):1157-1172. doi: 10.1093/eurheartj/ehac031
  • Di Filippo L, De Lorenzo R, D’Amico M, Sofia V et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr 2021 Apr;40(4):2420-2426. doi: 10.1016/j.clnu.2020.10.043
  • Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):863-865. doi: 10.1002/jcsm.12589
  • Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. J Card Fail. 2020. doi: 10.1016/j.cardf ail.2020.04.009
  • National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2020. Available online: https://www.nice.org.uk/guidance/ng188/chapter/context#post-covid-19-syndrome (accessed on 28 January 2021).
  • Toraih, EA, Elshazli, RM, Hussein, MH, Elgaml, A, Amin, M, El-Mowafy, M, et al.. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and decision tree analysis. J Med Virol 2020 Nov;92(11):2473-2488. doi: 10.1002/jmv.26166
  • Guzik TJ, Mohiddin SA, Dimarco A, Patel V, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 116: 1666–1687, 2020. doi:10.1093/cvr/cvaa106
  • Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, Wen WF, Wan CH, Wu XM, Chang YY, Wu VC, Wu KD, Lin YH, TAIPAI Study Group. IL-6 transsignalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res 2018; 114:690–702.
  • Watson C, Whittaker S, Smith N, Vora AJ, Dumonde DC, Brown KA. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 1996;105:112–119.
  • van Tits LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011;214:345–349.
  • Deftereos SG, Giannopoulos G, Vrachatis DA, et al Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e2013136. doi:10.1001/jamanetworkopen.2020.13136
  • Pourdowlat G, Saghafi F, Mozafari A, Sahebnasagh A et al Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial. Phytotherapy Research. 2022 Feb;36(2):891-898. doi: 10.1002/ptr.7319
  • COVID-19 Scientific Advisory Group Rapid Evidence Report Colchicine for the treatment of COVID-19, February 23, 2021
  • Zhen-Zhen Wang ZZ, Li K, Maskey AR, Huang W, Toutov AA. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. The FASEB Journal. 2021;35:e21360.
  • Zhang BY, Chen M, Chen XC, Cao K, You Y et al. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19 BJS, 2021, 108, e9–e11
  • Bernini R and Velotti F. Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19. Molecules 2021 Sep 25;26(19):5803. doi: 10.3390/molecules26195803
  • Saeedi-Boroujeni A and Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-19 treatment. Journal of Inflammation. 2021 Jan 28;18(1):3. doi: 10.1186/s12950-021-00268-6
  • Rattis BA, Ramos SG and Celes MR. Curcumin as a potencial treatment for COVID-19. Frontiers in pharmacology, 2021 May, v. 12, article 675287
  • Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC et al. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients. 2022 Jan 7;14(2):256. doi: 10.3390/nu14020256
  • Ruscica M., Penson P.E., Ferri N., Zhisheng J., Zirlik A. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular diseases. 2021 Jul-Aug;67:40-52. doi: 10.1016/j.pcad.2021.06.010
  • Heeba GH, Mahmoud ME, El Hanafy AA. Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-α. Toxicol Ind Health. 2014 Jul;30(6):551-60. doi: 10.1177/0748233712462444. Epub 2012 Sep 28.
  • Güran M, Şanlıtürk G, Kerküklü NR, Altundağ EM, Süha Yalçın A. Combined effects of quercetin and curcumin on anti-inflammatory and antimicrobial parameters in vitro. Eur J Pharmacol. 2019 Sep 15;859:172486. doi: 10.1016/j.ejphar.2019.172486. Epub 2019 Jun 25.
Еще
Статья научная
SciUp 2024 © 2024 ©